Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
Mon, 04.03.2024
Edison Investment Research Limited
London, UK, 4 März 2024
Edison issues update on abrdn Private Equity Opportunities Trust (APEO): Returns and buyback help narrow the discount
abrdn Private Equity Opportunities Trust (APEO) achieved a 5.4% NAV total return (TR) in FY23 (to end-September 2023) despite muted private equity (PE) deal activity and foreign exchange headwinds (it [ … ]
Mon, 04.03.2024
Edison Investment Research Limited
London, UK, 4 März 2024
Edison issues update on UIL (UTL): Long-term focus, avoiding short-term noise
UIL Limited (UIL) is managed by Charles Jillings and his highly experienced team at value-based specialist investor ICM. It is a unique portfolio of undervalued assets, which is illustrated by the fund’s differentiated exposures. In terms o [ … ]
Mon, 04.03.2024
Berlin Cures Holding AG
Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over 50% Patient Recruitment
Berlin Cures, a clinical-stage biotechnology firm, advances innovative treatment aimed at combating Long COVID, currently impacting over 100 million people globally.
Over 50% of patients in randomized placebo-controlled Phase-II-trial now recr [ … ]
Mon, 04.03.2024
Edison Investment Research Limited
London, UK, 4 März 2024
Edison issues update on MGI – Media and Games Invest (M8G): Back on a growth track
M8G had a good Q423, gaining market share in an improving trading environment. Organic revenue growth of 16% in the quarter helped lift the full year figure to +5%. This good momentum has continued into the new year, with 18% revenue g [ … ]
Mon, 04.03.2024
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx)
Heidelberg Pharma is eligible to receive up to USD 115 million in three near-term tranche [ … ]
Mon, 04.03.2024
Yandex N.V.
Yandex N.V. Reminds Shareholders of upcoming EGM and Class A Meeting
Amsterdam, the Netherlands, March 4, 2024 — Yandex N.V. would like to remind shareholders that the Company’s EGM and Class A Shareholders meetings are scheduled to take place on 7 March 2024. Yandex N.V. brings to shareholders for their approval the proposal to divest its Russ [ … ]
Mon, 04.03.2024
Defence Therapeutics Inc.
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceu [ … ]
Mon, 04.03.2024
Delivery Hero SE
Delivery Hero launches financing transaction to optimize its capital structure
Financing transaction launched to optimize and extend Delivery Hero’s existing EUR 1.1 billion equivalent term facilities and to raise one or more add-on term facilities in an aggregate amount of approximately EUR 500 million equivalent, with proceeds primarily used to [ … ]
Mon, 04.03.2024
Henkel AG & Co. KGaA
March 4, 2024
Accelerated implementation of strategic growth agenda in a challenging environment
Henkel delivers very strong organic sales growth and significant earnings improvement in 2023
Strong business performance in 2023
Sales: 21.5 billion euros, very strong organic growth of 4.2 percent
Operating profit (EBIT)*: 2.6 billion euros [ … ]
Mon, 04.03.2024
Douglas GmbH
Intention to Float (ITF)
DOUGLAS Group plans Initial Public Offering (IPO) on Frankfurt Stock Exchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REG [ … ]